ChemLifeIntel
CHEMICAL & LIFE SCIENCES INTELLIGENCE
Access
CLINICAL & PIPELINEClinical Trial CompletionNotable

Cairo University Completes Clinical Study NCT06069635 on Fatigue and Performance in Adolescent Football Players

CM
Catherine MorrowView Profile →
Senior Regulatory Intelligence Analyst
EXECUTIVE SUMMARY

Cairo University has completed its clinical study, NCT06069635, investigating the effect of fatigue on core endurance, dynamic balance, and player performance in adolescent football players. The interventional trial, involving 60 male participants from Wadi-Degla football club, provides critical data for sports medicine and performance science, impacting training protocols and injury prevention strategies in youth athletics.

Clinical Study Completion: Design and Objectives for Adolescent Athletes

Cairo University, a prominent institution in Egypt, has officially completed its interventional clinical study, NCT06069635, focusing on the critical area of fatigue in adolescent football players. This study, which commenced on May 17, 2022, and reached its primary completion on June 17, 2023, with overall completion by July 17, 2023, aimed to rigorously investigate the impact of fatigue on core endurance, dynamic balance, and overall player performance. For procurement directors and business development executives in sports technology and athletic development, understanding such research is vital. The study's design was a randomized, parallel-group interventional trial, enrolling 60 male participants aged 14 to 18 years. These players were specifically recruited from the Wadi-Degla football club's 2005, 2006, and 2007 teams in Giza, Egypt. The primary objective was to quantify the effects of fatigue, providing data that could directly influence the development of more effective training protocols and injury prevention strategies within youth sports programs. This comprehensive approach ensures that the findings are directly applicable to real-world athletic environments, offering tangible insights for stakeholders focused on optimizing young athletes' potential and safety.

Methodological Rigor and Participant Cohort Specifics

The methodological framework of the NCT06069635 study demonstrates a high degree of specificity, crucial for generating reliable data in sports science. Participants, all healthy male volunteers, were carefully selected based on stringent inclusion criteria: age between 14 and 18 years, active membership in Wadi-Degla football club teams, freedom from lower limb injuries for at least six months prior to the study, and an optimal Body Mass Index (BMI) ranging from 18.5 to 24.9. Exclusion criteria prevented participation from those not regularly trained for at least six hours per week, or with major lower limb injuries or surgery within the preceding six months. The 60 players were randomly assigned into two groups: a fatigue group (30 players) and a control group (30 players). Both groups underwent baseline assessments for core endurance, balance, and performance metrics including a 20-meter running sprint and the Triple-Hop Test (THT). The fatigue group then underwent a specific fatigue protocol utilizing Repeated Sprint Ability (RSA), while the control group followed a sham protocol. This detailed segmentation and rigorous assessment protocol ensures the validity of the findings, offering clear implications for how sports organizations evaluate and manage player readiness and fatigue levels.

Assessment Tools and Fatigue Protocol Implementation

A key aspect of the Cairo University study was the precise measurement of critical performance indicators. Single-leg balance was assessed using the 'MFT challenge disc' balance measuring system for both dominant and non-dominant legs, with measurements taken over a 20-second timeframe. This specific equipment choice provides a standardized and objective measure, highly relevant for procurement directors considering investments in advanced athletic assessment technologies. Core endurance was also evaluated, alongside performance metrics such as the 20-meter running sprint and the Triple-Hop Test (THT). The fatigue protocol applied to the experimental group involved a demanding Repeated Sprint Ability (RSA) test. This protocol consisted of six repetitions of maximal 2x15 meter shuttle sprints, interspersed with only 20 seconds of passive recovery, performed on an artificial grass carpet. A standardized 20-minute warm-up preceded the RSA protocol to ensure consistent physiological states. The fatigue index was calculated as a percentage decrement score, providing a quantitative measure of fatigue. This detailed methodology offers insights into specific assessment tools and training stressors that can be integrated into high-performance sports programs, influencing equipment procurement and training regimen design.

Implications for Sports Medicine and Performance Enhancement Strategies

The completion of Cairo University's NCT06069635 study carries significant implications for the global sports medicine and athletic development sectors. For regulatory affairs heads overseeing sports health guidelines and business development executives exploring new markets, the findings will contribute to evidence-based practices. By quantifying the direct effects of fatigue on balance and core endurance in adolescent football players, this research provides a scientific foundation for optimizing training loads and recovery strategies. Understanding how fatigue impacts these fundamental physical attributes can lead to the development of more sophisticated injury prevention programs, potentially reducing the incidence of musculoskeletal injuries in young athletes. Furthermore, the study's insights can inform talent identification and development programs, allowing coaches and trainers to better manage player workloads and enhance long-term athletic performance. This data is invaluable for organizations like Wadi-Degla football club, and others globally, seeking to implement cutting-edge sports science to gain a competitive edge and ensure the well-being of their players. The focus on a specific age group and sport makes the findings particularly relevant for targeted interventions in youth football academies worldwide.

Strategic Planning and Procurement in Youth Sports Development

For procurement directors and supply chain VPs within sports organizations, the outcomes of studies like NCT06069635 directly influence strategic planning and purchasing decisions. The explicit mention of the 'MFT challenge disc' for balance assessment, for example, highlights a specific technology that could become a standard procurement item for clubs and academies aiming to implement scientifically-backed performance monitoring. Similarly, the detailed description of the Repeated Sprint Ability (RSA) fatigue protocol provides a blueprint for designing training equipment and facilities. Organizations involved in youth sports development, including national federations and private academies, can leverage these findings to justify investments in specialized equipment, advanced physiological testing tools, and expert personnel trained in sports science. This could include procuring services from sports physiologists, investing in data analytics platforms to track player fatigue, or sourcing specific training apparatus designed to improve core endurance and dynamic balance. The study underscores the commercial value of integrating rigorous scientific research into athletic programs, guiding procurement strategies towards solutions that demonstrably enhance player safety, performance, and long-term athletic development, particularly within the competitive landscape of global football.

ChemLifeIntel analysis · Catherine Morrow. Compiled from primary and reported sources.
CHEMLIFEINTEL TERMINAL

Go deeper than the brief

The Terminal adds the full entity graph behind this story — downstream buyer-exposure mapping, alternative-supplier shortlists, 5-year compliance footprints and live supply-chain risk scores. Built for procurement, regulatory and business-development teams.

TERMINAL ACCESS
Request Terminal Access

Tell us where to send your access details — used by procurement and regulatory teams at 40+ pharmaceutical companies.

Used by procurement and regulatory teams at 40+ pharmaceutical companies
CONNECTED COVERAGE

Related Intelligence

CLINICAL & PIPELINE
40 min ago

Boston University's SLATE Study Completes, Signaling Shift in Global HIV Antiretroviral Therapy Initiation Protocols

Boston University has completed its SLATE clinical study (NCT02891135), evaluating a simplified algorithm for immediate HIV antiretroviral therapy (ART) initiation. This development signals a potential shift in global treatment protocols, particularly in sub-Saharan Africa, with significant implications for ART procurement, supply chain logistics, and market demand for pharmaceutical companies operating in the HIV/AIDS therapy area.

CLINICAL & PIPELINE
3h ago

J&J's MonumenTAL-3 Phase 3 Data for Talvey and Darzalex Faspro Signals Major Shift in Earlier Multiple Myeloma Treatment

J&J's MonumenTAL-3 Phase 3 study, combining bispecific antibody Talvey with Darzalex Faspro for earlier-stage multiple myeloma, has secured a plenary presentation at the 2026 EHA meeting. This signals robust data, positioning J&J to expand its market presence and potentially redefine treatment paradigms for this patient population, impacting competitive strategies and future procurement decisions.

CLINICAL & PIPELINE
5h ago

CinnaGen's Zandoriah®: First EU Authorization for Teriparatide Biosimilar in Osteoporosis Across 30 EEA States

CinnaGen has secured its first EU authorization for Zandoriah®, a Teriparatide biosimilar for osteoporosis, approved by the European Commission. This marks a significant market entry across 30 EEA states, leveraging CinnaGen's manufacturing investments. Decision-makers must assess new supply chain opportunities and competitive shifts in the European bone health market.

CLINICAL & PIPELINE
7h ago

WHO Strengthens Global Clinical Trial Transparency and Good Practices: Implications for Pharma Supply Chains

The World Health Organization (WHO) is advancing global clinical trial transparency and good practices through new initiatives, including an online course, a paediatric research agenda, and the Global Clinical Trials Forum. These efforts, detailed by the ICTRP, aim to strengthen trial environments and data accessibility. For companies like Skip, this signifies a heightened focus on ethical conduct, regulatory compliance, and strategic adjustments in clinical development pipelines.

CLINICAL & PIPELINE
7h ago

Strategic Imperative: Leveraging FDA Orange Book Data Files for Chemical and Life Sciences Market Intelligence

The FDA's Orange Book Downloadable Data Files offer critical intelligence for chemical and life sciences executives. This resource details approved drug products, patent information, and exclusivity periods, enabling procurement, regulatory, and business development teams to strategize generic market entry, monitor intellectual property, and ensure supply chain compliance. Understanding these data structures is paramount for competitive advantage.

CLINICAL & PIPELINE
7h ago

FDA Enhances Drug Master File Reviews Under GDUFA III: Strategic Implications for API Supply and Generic Market Access

The FDA's GDUFA III enhancements for Drug Master Files (DMFs) streamline API review, accelerating generic drug approvals. This regulatory shift offers significant commercial advantages for API manufacturers like Hetero Drugs and generic drug developers, impacting procurement, supply chain, and market entry strategies in the global chemical and life sciences industry.

CLINICAL & PIPELINE
7h ago

TG Therapeutics Halts Phase 1b Trial for Novel CD47/CD19 Bispecific TG-1801 in B-Cell Lymphoma and CLL

TG Therapeutics, Inc. has terminated its Phase 1b clinical trial (NCT04806035) for TG-1801, a novel CD47/CD19 bispecific antibody, citing a "Strategic/Business Decision." This impacts the oncology pipeline, halting development for B-cell lymphomas and CLL. Procurement and regulatory teams must reassess future supply chain needs and market opportunities in this therapeutic area.

CLINICAL & PIPELINE
7h ago

Inhibrx Biosciences' Ozekibart BLA Acceptance Signals New Treatment Horizon for Chondrosarcoma

Inhibrx Biosciences has achieved a critical milestone with the US FDA's BLA acceptance for ozekibart (INBRX-109) to treat unresectable or metastatic conventional chondrosarcoma. This development, backed by robust ChonDRAgon study data, sets a PDUFA date of April 14, 2027, and signals a significant commercial opportunity for Inhibrx in an area of high unmet medical need, impacting procurement and regulatory strategies.

CLINICAL & PIPELINE
8h ago

FiberSense Secures CE Mark for CGM System: Strategic Entry into European Diabetes Management Market

FiberSense has achieved CE Marking for its Continuous Glucose Monitoring (CGM) System, a Class IIb medical device for adults with diabetes. This approval unlocks market access across the European Union, with initial deliveries slated for late 2026. This development signals a new competitive entrant in the diabetes care sector, necessitating strategic evaluation by procurement and business development teams.

CLINICAL & PIPELINE
10h ago

Edgewise Therapeutics' EDG-7500 Phase 2 Data Shows Strong Efficacy in Hypertrophic Cardiomyopathy

Edgewise Therapeutics has reported compelling Phase 2 data for EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy. The oral therapy demonstrated significant improvements across key cardiac and quality-of-life metrics, positioning it as a promising candidate. This early validation signals potential for future market entry, influencing strategic planning for procurement, regulatory, and business development teams in cardiology.

CLINICAL & PIPELINE
1d ago

GLP-1 Persistence Study Reveals Critical Discontinuation and Reinitiation Trends for Type 2 Diabetes Management

A new study on GLP-1 drug usage reveals significant patient discontinuation rates, with many reinitiating therapy. Newer molecules like tirzepatide and semaglutide show superior persistence. This 'start-and-stop' pattern necessitates agile supply chain strategies and targeted patient support to ensure consistent treatment and optimize commercial outcomes for type 2 diabetes and obesity therapies.

CLINICAL & PIPELINE
2d ago

Cu(ATSM) Copper Drug Shows Preclinical Alzheimer's Breakthrough, Poised for Fast-Track Clinical Development

Monash University's preclinical research reveals Cu(ATSM), a copper-based compound, significantly reduces toxic amyloid-beta proteins by 42% and improves spatial memory by 44% in Alzheimer's models. This breakthrough, published June 16, 2026, is poised for accelerated clinical development, leveraging existing human safety data from Parkinson's and ALS trials. This offers a fast-track opportunity for pharmaceutical companies seeking novel neurovascular-targeting Alzheimer's therapies, impacting future procurement and market strategies.

ENTITY HUBS

Entities in this Brief

Section
company hub
Open company hub